ABT-263, a senolytic compound that selectively eliminates aged cells, reduced both acute lung inflammation and long-term respiratory damage in aged mice infected with influenza. The B-cell lymphoma-2 inhibitor didn't prevent initial infection severity or weight loss, but significantly dampened inflammatory responses and prevented chronic complications including lung edema, emphysema, and tissue damage. The treatment also reduced gut inflammation and restored intestinal microbiome balance disrupted by the virus.
This represents a potentially transformative approach to managing respiratory infections in aging populations. Rather than targeting the virus directly, senolytics address the underlying cellular aging that makes older adults vulnerable to severe outcomes. The age-dependent effects suggest pre-existing senescent cells amplify inflammatory cascades during infection. While promising, this mouse study has limitations—the compound reduced protective T-cell responses, raising questions about immune trade-offs. The findings align with growing evidence that cellular senescence drives age-related disease vulnerability, positioning senolytics as preventive therapeutics for infectious disease complications in older adults rather than acute treatments.
